

Antibiotic Susceptibility Patterns of *Pseudomonas aeruginosa* Isolated from ICU PatientsNeelam Kumari¹, Basavaraja Channabasappa Hunasemarada², Pushpa Rani³¹Senior resident, Department of Microbiology, Netaji Subhash Medical College and Hospital Jamshedpur, Jharkhand, India²Professor and HOD, Department of Microbiology, Netaji Subhash Medical College and Hospital Jamshedpur, Jharkhand, India³Junior Resident, Department of Pathology, SKMCH Muzaffarpur, Bihar, India

Received: 11-01-2026 / Revised: 13-02-2026 / Accepted: 16-03-2026

Corresponding Author: Neelam Kumari

Conflict of interest: Nil

Abstract:**Background:** *Pseudomonas aeruginosa* is a prevalent opportunistic pathogen responsible for infections in patients with cancer. The objective of the study was to assess the antibiotic susceptibility of *Pseudomonas aeruginosa* and multidrug-resistant (MDR) isolates in ICU patients.**Methods:** A retrospective study was performed from January 2024 to December 2024 at Netaji Subhas Medical College, Jamshedpur. A total of 111 unique clinical isolates of *P. aeruginosa* were collected from patients in several ICUs, encompassing medical, surgical, and neonatal units. The isolates were identified by established techniques utilizing biochemical assays. The antibiotic susceptibility profile of each isolate was assessed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines 2022.**Results:** Of the 111 clinical samples, the predominant *P. aeruginosa* isolates were obtained from respiratory specimens. The majority of isolates exhibited sensitivity to colistin (98.1%, n=109) and amikacin (66.6%, n=74); however, resistance to ciprofloxacin, ceftazidime, and levofloxacin was notably higher at 51.8%, 49.6%, and 49.6%, respectively.**Conclusions:** This hospital-based retrospective study aims to enhance infection control tactics and augment doctors' understanding of antibiotic resistance patterns. Consequently, an antibiotic stewardship program is necessary to monitor resistance patterns at a tertiary care cancer hospital.**Keywords:** Multidrug Resistance, Extensively Drug Resistance, *Pseudomonas aeruginosa*, Antibiotic Resistance, Clinical Samples, Surgical Wards, Hospital Environment.**DOI:** 10.25258/ijcpr.18.3.275This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.**Introduction**

Pseudomonas aeruginosa is a predominant etiological agent of healthcare-associated infections, especially in intensive care units (ICUs), where patients are severely ill, immunocompromised, and often subjected to invasive equipment and broad-spectrum antibiotics [1], [2]. This opportunistic bacterium causes ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and surgical site infections, and is linked to elevated morbidity and mortality rates [3].

A significant difficulty in managing *P. aeruginosa* infections is its extraordinary capacity to build resistance to several antibiotic classes via intrinsic resistance mechanisms, acquisition of resistance genes, efflux pumps, and biofilm formation [4]. The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) *P. aeruginosa*

strains in intensive care units (ICUs) significantly restricts treatment alternatives [5], [6].

Understanding local antibiotic susceptibility patterns is crucial for directing empirical treatment, enhancing antimicrobial stewardship, and elevating patient outcomes [7]. This study sought to identify the antibiotic susceptibility profile of *P. aeruginosa* isolated from ICU patients.

Methods

Study Design and Setting: This retrospective cross-sectional study was conducted in the Netaji subhash medical college in India over a period of one year (January 2024–December 2024).

Study Isolates: A total of 111 non-duplicate clinical isolates of *P. aeruginosa* were obtained from patients admitted to various ICUs, including medical, surgical, and neonatal ICUs.

Inclusion Criteria

- Clinical samples from ICU patients yielding *P. aeruginosa*
- Only the first isolate per patient was included

Exclusion Criteria

- Duplicate isolates from the same patient
- Environmental isolates

Identification of *P. aeruginosa*: Isolates were identified based on colony morphology, Gram staining, oxidase test, pigment production, growth at 42°C, and standard biochemical tests.

Antibiotic Susceptibility Testing: Antibiotic susceptibility testing was performed using the Kirby–Bauer disc diffusion method on Mueller–Hinton agar. The antibiotics tested included:

- Piperacillin–tazobactam
- Ceftazidime
- Cefepime
- Amikacin

- Gentamicin
- Ciprofloxacin
- Levofloxacin
- Colistin

Results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines.

Definition of Multidrug Resistance: MDR *P. aeruginosa* was defined as resistance to at least one agent in three or more antimicrobial classes.

Statistical Analysis: Data were entered into Microsoft Excel and analyzed descriptively. Results were expressed as frequencies and percentages.

Results

Distribution of Clinical Samples: The majority of *P. aeruginosa* isolates were recovered from respiratory samples.

Table 1: Distribution of Clinical Samples (n=111)

Sample Type	Number	Percentage (%)
Endotracheal aspirate	38	34.23
Sputum	23	20.7
Blood	18	15.0
Urine	20	16.7
Wound/pus	12	10.8

Antibiotic Susceptibility Pattern: Colistin, fluoroquinolones and third-generation cephalosporins showed the highest susceptibility, while cephalosporins showed lower susceptibility rates.

Table 2: Antibiotic Susceptibility Pattern of *P. aeruginosa*

Antibiotic	Sensitive n (%)	Resistant n (%)
Piperacillin–tazobactam	72 (64.8)	39 (35.2)
Ceftazidime	56 (50.4)	55 (49.6)
Cefepime	60 (54.0)	51 (46)
Amikacin	74 (66.6)	37 (33.4)
Gentamicin	62 (55.8)	49 (44.2)
Ciprofloxacin	54 (48.6)	57 (51.8)
Levofloxacin	56 (50.4)	55 (49.6)
Colistin	109 (98.1)	2 (1.9)

Multidrug Resistance Pattern: Out of 111 isolates, 41 (38.3%) were identified as multidrug-resistant *P. aeruginosa*.

Table 3: Prevalence of Multidrug Resistance

Resistance Pattern	Number	Percentage (%)
MDR isolates	41	36.9
Non-MDR isolates	70	63.0

Discussion

This study emphasizes a troubling degree of antibiotic resistance in *P. aeruginosa* isolates collected from ICU patients. Respiratory specimens, especially endotracheal aspirates, were the predominant source, indicating the significant

prevalence of ventilator-associated infections in intensive care units [8].

Moderate susceptibility to antipseudomonal beta-lactams was noted, however resistance to fluoroquinolones was significantly elevated. The identification of MDR *P. aeruginosa* in over one-third of isolates highlights the selection pressure

imposed by extended ICU admissions and intensive antibiotic usage.

Colistin had exceptional efficacy against *P. aeruginosa* isolates, affirming its status as a last-resort antibiotic. The emergence of colistin resistance, however minimal, is concerning and necessitates rigorous antimicrobial stewardship and infection control measures [9].

Limitations

Testing for minimum inhibitory concentration (MIC) and molecular identification of resistance mechanisms were not conducted. This was a unicentric study.

Conclusion

Pseudomonas aeruginosa isolated from ICU patients showed elevated resistance to frequently utilized antibiotics, with a significant prevalence of multidrug-resistant isolates. Consistent monitoring of antibiotic susceptibility trends and prudent application of antimicrobials are crucial for informing empirical treatment and mitigating the dissemination of resistant *P. aeruginosa* in intensive care units.

References

1. Bertrand X, Thouverez M, Patry C, Balvay P, Talon DÁ. *Pseudomonas aeruginosa*: antibiotic susceptibility and genotypic characterization of strains isolated in the intensive care unit. *Clin Microbiol Infect* [Internet]. 2001;7(12):706–8. Available from: <http://dx.doi.org/10.1046/j.1469-0691.2001.00348.x>
2. Eid R, Dabar G, Hanna L, Saliba G, Riachy M, Choucair J, et al. Comparison of antimicrobial resistance in *Pseudomonas aeruginosa* from intensive care and non-intensive care units and its impact on treatment decisions. 2025;1–7.
3. Das S, Venugopal KE, Prasad S. Antibiotic Susceptibility Pattern and Clinical Profile of *Pseudomonas aeruginosa* Isolated from Lower Respiratory Tract Samples: A Cross-sectional Study. 2026;10–4.
4. Al-zaidi JR. Antibiotic susceptibility patterns of *Pseudomonas aeruginosa* isolated from clinical and hospital environmental samples in Nasiriyah, Iraq. 2016;10(23):844–9.
5. Kallel H, Mahjoubi F, Dammak H, Bahloul M, Hamida C Ben, Chelly H, et al. Correlation between antibiotic use and changes in susceptibility patterns of *Pseudomonas aeruginosa* in a medical-surgical intensive care unit. 2003.
6. Rao TR and US. Prevalence and Resistance pattern of *Pseudomonas* strains isolated from ICU Patients. 2014;3(3):527–34.
7. Negi S, Ramanath K, Bala L, Sharma MK. Antibiotic susceptibility patterns of *Pseudomonas* sp. isolated from various clinical samples at a tertiary care hospital at Dewas in Madhya Pradesh, India. 2021;8(1):65–70.
8. Surve K V, Khaparkhantkar MN, Siddiqui NS, Irvane JA. Antibiotic resistance pattern of *Pseudomonas aeruginosa* isolated from pus samples at tertiary care cancer hospital. 2024;12(4):1209–14.
9. Parveen R, Chand AE. Isolation Of *Pseudomonas aeruginosa* from Various Clinical Samples and Its Correlation with Biofilm and Antimicrobial Susceptibility Pattern at Tertiary Care Centre. 2024; (06):612–5.